StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $3.07 | $2.82 | -8.14% | 1.3M |
| 05-12 | $2.82 | $2.87 | +1.77% | 0.7M |
| 05-13 | $2.93 | $2.95 | +0.68% | 0.8M |
| 05-14 | $2.98 | $3.21 | +7.72% | 1.5M |
| 05-15 | $3.25 | $3.42 | +5.08% | 1.2M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
| Metric | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $1.23M | $242.00K | $0.00 | $0.00 |
Operating Income | $-16.22M | $-11.60M | $-7.58M | Not available |
Net Income | $-28.62M | $-28.98M | $-17.58M | $-5.51M |
EPS (Diluted) | $-1.34 | $-1.54 | $-1.34 | Not available |
Total Assets | $12.96M | $15.00M | $4.84M | $7.59M |
Total Liabilities | $28.89M | $40.75M | $40.45M | $32.75M |
Cash & Equivalents | $7.80M | $7.18M | $2.91M | $5.55M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | $-3.48M |
Shares Outstanding | 31.73M | 27.68M | 19.47M | 17.12M |